Health Care • Biotechnology: Pharmaceutical Preparations
$29.73 ▼ -1.29
(-4.16%)
MKT CAP: $5.38B • VOL: 2.00M
52W L $14 52W H $44
COGT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $933.4M | $772.6M | $582.8M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$333.4M | -$275.9M | -$208.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$328.9M | -$255.9M | -$192.4M |
| EBITDA (Normalized) | -$332.1M | -$275.5M | -$208.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$264.4M | -$207.8M | -$153.6M |
| Capital Expenditures (CapEx) | $1.6M | $573.0K | $0 |
| Free Cash Flow (FCF) | -$266.0M | -$208.4M | -$153.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -8.9% |
| Cash & Short-Term Equivalents | $312.0M | $98.2M | — |
| Total Debt (Short + Long Term) | $135.6M | $0 | $713.8M |
| Total Stockholders' Equity | $636.4M | $256.3M | $1.46B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COGT.